NEW YORK (GenomeWeb News) – DiaGenic said today that lab services firm DNAVision will offer the firm’s blood-based gene expression tests for early detection of breast cancer and Alzheimer’s disease.
The Oslo-based molecular diagnostics firm said that DNAVision would offer the tests through its CLIA/ISO17025-certified facilities.
DiaGenic said it is in the process of introducing the breast cancer test in India. It expects to CE Mark the tests early next year and then seek clearance in the US sometime in the future.
“In parallel to this agreement, we are finalizing the distribution channels in preparation for a full European launch in early next year following CE marking of both the breast cancer and the Alzheimer’s disease test,” DiaGenic CEO Erik Christensen said in a statement.